Blisibimod

Drug Profile

Blisibimod

Alternative Names: A-623; AMG-623

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II/III IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 01 Oct 2016 Anthera Pharmaceuticals completes the phase III CHABLIS-SC1 in Systemic lupus erythematosus in Brazil, Georgia, Hong Kong, Philippines, Russia, Singapore, Sri Lanka, Mexico, Taiwan, Belarus, Colombia, Guatemala, Malaysia, South Korea, India and Thailand (NCT01395745)
  • 28 Jun 2016 Interim efficacy and adverse events data from a phase II trial in IgA Nephropathy released by Anthera Pharmaceuticals
  • 01 Jun 2016 Anthera Pharmaceuticals initiates the phase III CHABLIS 7.5 trial for Systemic lupus erythematosus in Georgia(NCT02514967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top